Chengdu Maxvax Biotechnology LLC

Ab&B Bio-Tech\'s pipeline puts it on a collision course with U.S. drugmakers. \n Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with companies including GSK, Merck & Co. and Pfizer.China-based Ab&B won approval for a quadrivalent flu vaccine in its home market in 2023. The flu shot is one of two core products that will swallow up around half of the anticipated IPO haul. Ab&B’s other core product is a rabies vaccine candidate that is scheduled to enter phase 3 in the second or third quarter. China already has 23 approved human rabies vaccines but only two that use similar tech to Ab&B’s shot.Ab&B will go up against other local manufacturers if it launches the rabies vaccine in China but the rest of its pipeline could pit it against big Western drugmakers. The biotech has allocated around one-quarter of the expected IPO monies to advancing the rest of its portfolio.A phase 3 trial of a 23-valent pneumococcal disease vaccine candidate is the biggest anticipated outlay in the non-core pipeline. Ab&B plans to start the study around the end of the year. If successful, the trial will position Ab&B to enter a market that is already served by Merck’s 23-valent vaccine Pneumovax and Pfizer’s 13-valent shot Prevnar 13. Another Ab&B program puts the biotech on a collision course with GSK. A phase 1 trial of a shingles shot is set to start this quarter. Currently, GSK’s Shingrix is the only recombinant vaccine against herpes zoster, also known as shingles, approved for use in China. However, Ab&B’s chances of launching the second recombinant shot look slim, with Recbio, Lvzhu Biotech and MaxVax already in phase 3.Ab&B has also ceded a head start to its rivals in the respiratory syncytial virus (RSV) vaccine race. China is yet to approve a RSV vaccine, unlike the U.S. which has given the green light to shots from GSK, Moderna and Pfizer, but multiple candidates have reached the clinic ahead of Ab&B. A filing to test Ab&B’s vaccine candidate in humans is planned for around the middle of the year.The biotech is seeking funding for the programs from investors who have plenty of IPOs to pick from. Ab&B is one of eight biotechs that have filed to go public in Hong Kong over the past month and one of three to file paperwork this week. The filings have swelled the backlog of biotech IPOs toward 20, with Duality Biotherapeutics, Zephyrm Bioscience and other companies that filed last year still in the queue. 

Chinese companies Maxvax Biotechnology and Beijing Luzhu Biotechnology are raising funds to move their respective research and development programs for recombinant herpes zoster (shingles) vaccine candidates and new adjuvant products. Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment, with support from Sherpa Investment, Hillhouse Venture Capital, Fangshizhen Capital and Xinshang Capital. The company plans to use the money to fund multiple clinical trials in its vaccine pipeline, which includes potential treatments for herpes zoster and rotavirus for neonates and children under 5 years old. Scrip reported the vaccine is being developed to rival GSK's Shingrix, one of its highest-grossing products. It also wants to expand its workforce and set up a production facility in Shanghai. "This round of funding demonstrates that shareholders value Maxvax's team and technology, and it will assist the company in advancing clinical trials and industrializing key products. Maxvax will strive to develop better vaccines made in China with the recognition and support of investment institutions," Dr. Dexiang Chen, founder and general manager of MaxVax, said. Maxvax owns an adjuvant platform, a recombinant protein expression platform and an mRNA platform that are used globally. Other items under development include preventive and therapeutic vaccines for the likes of cancer, hepatitis B and allergies. Currently, the company has over 130 staff across R&D centers in different parts of China. Beijing Luzhu Biotech To Pour 40% Of IPO Proceeds Into Herpes Zoster Vaccine Beijing Luzhu Biotechnology, which filed for an initial public offering in Hong Kong in June, intends to use 40% of the funds it raises to develop its herpes zoster vaccine candidate LZ901, according to a report by Chinese news agency PharmaDJ. LZ901 is its core product, which the company claims could become the first of its kind in the world with a tetrameric molecular structure. It is designed to prevent shingles in adults ages 50 years and up. The Phase II clinical trial for the drug is expected to be completed by the fourth quarter of this year, and if all goes well, Phase III will likely begin in the first quarter of 2023. The company plans to a New Drug Application locally by the second quarter of 2024. Beijing Luzhu also intends to reach the United States market with Phase I/II clinical trials planned for 2023. LZ901 is not the only product it is focusing on, as it also said it is allocating 12.2% of its IPO proceeds to K3, a core product that is a biosimilar to adalimumab. According to its website, K3 is designed to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and other autoimmune disorders. Other candidates in R&D include a K193 antibody injection for B-cell lymphoma, currently undergoing a dose escalation study, a K333 antibody injection for myeloid leukemia and an EK193 antibody injection for lymphoma.

male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man’s hand close-up on a dark background. hundred Diy13/Getty Images/iStockphoto Maxvax and Luzhu are raising funds to move their respective research and development programs for recombinant herpes zoster vaccine candidates and new adjuvant products. Chinese companies Maxvax Biotechnology and Beijing Luzhu Biotechnology are raising funds to move their respective research and development programs for recombinant herpes zoster (shingles) vaccine candidates and new adjuvant products. Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment, with support from Sherpa Investment, Hillhouse Venture Capital, Fangshizhen Capital and Xinshang Capital. The company plans to use the money to fund multiple clinical trials in its vaccine pipeline, which includes potential treatments for herpes zoster and rotavirus for neonates and children under 5 years old. Scrip reported the vaccine is being developed to rival GSK’s Shingrix, one of its highest-grossing products. It also wants to expand its workforce and set up a production facility in Shanghai. “This round of funding demonstrates that shareholders value Maxvax’s team and technology, and it will assist the company in advancing clinical trials and industrializing key products. Maxvax will strive to develop better vaccines made in China with the recognition and support of investment institutions,” Dr. Dexiang Chen, founder and general manager of MaxVax, said. Maxvax owns an adjuvant platform, a recombinant protein expression platform and an mRNA platform that are used globally. Other items under development include preventive and therapeutic vaccines for the likes of cancer, hepatitis B and allergies. Currently, the company has over 130 staff across R&D centers in different parts of China. Beijing Luzhu Biotech To Pour 40% Of IPO Proceeds Into Herpes Zoster Vaccine Beijing Luzhu Biotechnology, which filed for an initial public offering in Hong Kong in June, intends to use 40% of the funds it raises to develop its herpes zoster vaccine candidate LZ901, according to a report by Chinese news agency PharmaDJ . LZ901 is its core product, which the company claims could become the first of its kind in the world with a tetrameric molecular structure. It is designed to prevent shingles in adults ages 50 years and up. The Phase II clinical trial for the drug is expected to be completed by the fourth quarter of this year, and if all goes well, Phase III will likely begin in the first quarter of 2023. The company plans to a New Drug Application locally by the second quarter of 2024. Beijing Luzhu also intends to reach the United States market with Phase I/II clinical trials planned for 2023. LZ901 is not the only product it is focusing on, as it also said it is allocating 12.2% of its IPO proceeds to K3, a core product that is a biosimilar to adalimumab. According to its website, K3 is designed to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and other autoimmune disorders. Other candidates in R&D include a K193 antibody injection for B-cell lymphoma, currently undergoing a dose escalation study, a K333 antibody injection for myeloid leukemia and an EK193 antibody injection for lymphoma.